CSL names ViiV chief Deborah Waterhouse its first woman CEO
By Priya NairLeadership & Growth Editor, Peepals Shakti
Representative image: MagicDesk / Pixabay
Australian biotech CSL named ViiV Healthcare chief Deborah Waterhouse CEO from February 1, 2027, the first woman to lead the company, it said on October 21, 2026.
What Happened
CSL, the Australian biotechnology company, announced on 21 October 2026 that Deborah Waterhouse, chief executive of the HIV medicines company ViiV Healthcare, will become its Chief Executive Officer and Managing Director from 1 February 2027. Reports describe her as the first woman to lead CSL since it was incorporated more than three decades ago. The board said the decision was unanimous and followed a global search.
Key Facts
- Who: Deborah Waterhouse, currently CEO of ViiV Healthcare, the HIV medicines company linked to GSK.
- New role: CEO and Managing Director of CSL, from 1 February 2027.
- Announced: 21 October 2026.
- Interim leadership: Gordon Naylor continues as interim CEO and Managing Director until 1 February 2027, then returns to his role as a non-executive director.
- Background: she previously led GSK's US vaccines business and its US primary care business, and was GSK's general manager for Australia and New Zealand from 2008 to 2012.
- Base: she will be based in the United Kingdom and spend time in Australia, the United States and CSL's other major markets.
- Pay: a base salary of £1.5 million a year under her contract, according to reports.
- Her successor at ViiV: Lynn Baxter, president of GSK Europe, takes over from 1 November 2026.
Why It Matters
A first woman chief executive at a company of CSL's size is a milestone in itself, and reports have highlighted it as such. Waterhouse's appointment puts a woman in charge of a major global biotech group at a moment when its board is looking for a turnaround.
Her path shows how such leaders are often built: by running large businesses inside global companies across different countries and functions. She has led vaccines and primary care businesses in the US, a country business in Australia and New Zealand, and then a whole company at ViiV. CSL's chair, Dr Brian McNamee, called her "an outstanding global leader with a proven ability to grow complex businesses."
She also takes on a difficult job. CSL has been struggling to recover from its US$11.7 billion purchase of the iron-deficiency specialist Vifor Pharma in 2022, and the company dismissed its previous chief executive, Paul McKenzie, in February amid weak business performance. Trade press described the appointment as coming at one of the hardest moments in the company's history, which makes her role a test of turnaround leadership as much as a milestone.
The arrangements around the appointment are also worth noting. Waterhouse will lead the Australian company while based in the United Kingdom, travelling to Australia, the United States and CSL's other major markets, a pattern that reflects how global companies now pick leaders for experience rather than location. Her move also triggers a second senior appointment of a woman: Lynn Baxter, currently president of GSK Europe, will succeed her as ViiV's chief executive and become president of GSK Global Health from 1 November 2026.
| CSL leadership change | Detail |
|---|---|
| New CEO | Deborah Waterhouse |
| Start date | 1 February 2027 |
| Interim CEO until then | Gordon Naylor |
| Previous role | CEO, ViiV Healthcare |
| Base salary | £1.5 million a year |
Impact
Short-term: CSL continues under interim leadership until February 2027, while ViiV moves to new leadership under Lynn Baxter from 1 November 2026.
Long-term: Waterhouse will be judged on whether she can restore growth and investor confidence at CSL. Her appointment adds to a small but growing list of women leading major global healthcare companies, which can widen the pipeline of women considered for such roles.
Who is affected: CSL's employees, patients who use its medicines, and shareholders; ViiV Healthcare and GSK; and women building careers in pharmaceutical and biotech leadership, including in India's large pharma sector.
Key Takeaway
Deborah Waterhouse becomes CSL's first woman chief executive in February 2027, taking charge of a turnaround at one of the world's major biotech companies.
Questions and Answers
Who is CSL's new CEO?
Deborah Waterhouse, currently chief executive of ViiV Healthcare, was named CSL's CEO and Managing Director on 21 October 2026. She takes up the role on 1 February 2027.
Is Deborah Waterhouse the first woman to lead CSL?
Yes, according to reports she is the first woman to lead CSL since the company was incorporated more than three decades ago.
Who runs CSL until she starts?
Gordon Naylor remains interim CEO and Managing Director until 1 February 2027, after which he returns to the board as a non-executive director.
What challenges will she face at CSL?
CSL is trying to recover from its US$11.7 billion acquisition of Vifor Pharma in 2022 and from weak performance that led to the dismissal of its previous chief executive in February.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
By Priya Nair, Leadership & Growth EditorCovers Leadership & Growth and more for Peepals Shakti. All stories by Priya Nair
Bengaluru apparel brand ReplyAll raises Rs 9.7 crore for 'all-day' clothing
Excess pregnancy weight gain tied to severe maternal complications: study
Get the day's stories in your inbox
Peepals Weekly: the week decoded, free. One email a week, unsubscribe in one click.
Priya Nair is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.
